333 related articles for article (PubMed ID: 36232561)
1. Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy.
Buyana B; Naki T; Alven S; Aderibigbe BA
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232561
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
[TBL] [Abstract][Full Text] [Related]
4. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
5. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.
Bruno PM; Liu Y; Park GY; Murai J; Koch CE; Eisen TJ; Pritchard JR; Pommier Y; Lippard SJ; Hemann MT
Nat Med; 2017 Apr; 23(4):461-471. PubMed ID: 28263311
[TBL] [Abstract][Full Text] [Related]
6. Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin-A Review.
Szefler B; Czeleń P
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675064
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin: a review of preclinical and clinical studies.
Raymond E; Chaney SG; Taamma A; Cvitkovic E
Ann Oncol; 1998 Oct; 9(10):1053-71. PubMed ID: 9834817
[TBL] [Abstract][Full Text] [Related]
8. Platinum anticancer drugs. From serendipity to rational design.
Monneret C
Ann Pharm Fr; 2011 Nov; 69(6):286-95. PubMed ID: 22115131
[TBL] [Abstract][Full Text] [Related]
9. What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin?
Lokich J
Cancer Invest; 2001; 19(7):756-60. PubMed ID: 11577818
[No Abstract] [Full Text] [Related]
10. Persistence of Oxaliplatin Transfer into Human Milk: A Case Report.
Krutsch K; Adams K; Shinwari M; Baucom RB
Breastfeed Med; 2023 May; 18(5):395-399. PubMed ID: 37093108
[No Abstract] [Full Text] [Related]
11. Platinums: extending their therapeutic spectrum.
Muggia FM; Fojo T
J Chemother; 2004 Nov; 16 Suppl 4():77-82. PubMed ID: 15688617
[TBL] [Abstract][Full Text] [Related]
12. Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane.
Yu CW; Li KK; Pang SK; Au-Yeung SC; Ho YP
Bioorg Med Chem Lett; 2006 Mar; 16(6):1686-91. PubMed ID: 16386904
[TBL] [Abstract][Full Text] [Related]
13. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
Pang SK; So WK; Ho YP; Au-Yeung CF
Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
15. Current status of oxaliplatin in colorectal cancer.
O'Dwyer PJ; Johnson SW
Semin Oncol; 2003 Jun; 30(3 Suppl 6):78-87. PubMed ID: 12802798
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin. A platinum compound for colorectal cancer?
Balzer KM
Cancer Pract; 2000; 8(4):201-3. PubMed ID: 11898261
[No Abstract] [Full Text] [Related]
17. [Oxaliplatin: the first DACH platinum in clinical practice].
Soulié P; Raymond E; Brienza S; Cvitkovic E
Bull Cancer; 1997 Jun; 84(6):665-73. PubMed ID: 9295871
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].
Chatelut E
Bull Cancer; 2011 Nov; 98(11):1253-61. PubMed ID: 22024542
[TBL] [Abstract][Full Text] [Related]
19. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
[TBL] [Abstract][Full Text] [Related]
20. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells.
Sundaramoorthy P; Ramasamy T; Mishra SK; Jeong KY; Yong CS; Kim JO; Kim HM
Acta Biomater; 2016 Sep; 42():220-231. PubMed ID: 27395829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]